Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

196
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
196
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

258
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
258
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

218
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
218
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

175
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
175
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

229
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
229
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

401
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
401

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Routine admission biomarkers for identifying co-infection and stratifying severity in pediatric macrolide-resistant <i>Mycoplasma pneumoniae</i> pneumonia: a retrospective cohort study.

Translational pediatrics·2026
Same author

Radiomics using contrast-enhanced T1-weighted imaging and clinical features for predicting response to EGFR-TKIs in EGFR-mutated non-small cell lung cancer patients with brain metastases.

BMC medical imaging·2026
Same author

Chlorine-induced severe ARDS in an adolescent rescued with VV-ECMO: a case report with 6-month functional follow-up.

Frontiers in pediatrics·2026
Same author

Magnetic resonance imaging characteristics of brain metastases from lung cancer.

Quantitative imaging in medicine and surgery·2026
Same author

Disturbed flow induced targeting of nanomedicine to endothelial cells for effective atherosclerosis therapy.

Cardiovascular research·2026
Same author

Guidewire incarceration in the femoral vein in a 6-month-old Boy.

Journal of cardiothoracic surgery·2026

Related Experiment Video

Updated: Sep 1, 2025

Ultrasound-guided Intracardiac Injection of Human Mesenchymal Stem Cells to Increase Homing to the Intestine for Use in Murine Models of Experimental Inflammatory Bowel Diseases
07:45

Ultrasound-guided Intracardiac Injection of Human Mesenchymal Stem Cells to Increase Homing to the Intestine for Use in Murine Models of Experimental Inflammatory Bowel Diseases

Published on: September 1, 2017

12.2K

Stem Cell-Based Therapies for Inflammatory Bowel Disease.

Hua-Min Zhang1,2, Shuo Yuan1,2, Huan Meng2

  • 1Key Laboratory of Natural Resources of Changbai Mountain & Functional Molecules, Ministry of Education, Molecular Medicine Research Center, College of Pharmacy, Yanbian University, Yanji 133002, China.

International Journal of Molecular Sciences
|August 12, 2022
PubMed
Summary

Stem cell therapy shows promise for treating inflammatory bowel disease (IBD) by reducing inflammation and improving patient outcomes. Further research is needed to confirm its long-term safety and effectiveness for IBD patients.

Keywords:
Crohn’s diseasehematopoietic stem cellsinflammatory bowel diseasemesenchymal stem cellsstem cell therapyulcerative colitis

More Related Videos

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

5.5K
Tissue Engineering of the Intestine in a Murine Model
08:45

Tissue Engineering of the Intestine in a Murine Model

Published on: December 1, 2012

15.0K

Related Experiment Videos

Last Updated: Sep 1, 2025

Ultrasound-guided Intracardiac Injection of Human Mesenchymal Stem Cells to Increase Homing to the Intestine for Use in Murine Models of Experimental Inflammatory Bowel Diseases
07:45

Ultrasound-guided Intracardiac Injection of Human Mesenchymal Stem Cells to Increase Homing to the Intestine for Use in Murine Models of Experimental Inflammatory Bowel Diseases

Published on: September 1, 2017

12.2K
In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

5.5K
Tissue Engineering of the Intestine in a Murine Model
08:45

Tissue Engineering of the Intestine in a Murine Model

Published on: December 1, 2012

15.0K

Area of Science:

  • Gastroenterology
  • Immunology
  • Regenerative Medicine

Background:

  • Inflammatory bowel disease (IBD) is a chronic condition impacting quality of life, with uncertain etiology involving immune, genetic, and microbial factors.
  • Current treatments for IBD are often insufficient, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To review emerging stem cell therapy methods for clinical application in IBD.
  • To analyze the results of ongoing clinical trials for stem cell transplantation in IBD patients.

Main Methods:

  • Review of current literature on stem cell therapy for IBD.
  • Analysis of clinical trial data for hematopoietic and mesenchymal stem cell therapies.

Main Results:

  • Stem cell therapy, including hematopoietic and mesenchymal stem cell types, demonstrates potential in improving clinical disease activity in IBD.
  • Stem cell transplantation has shown effectiveness in refractory IBD and potential for long-term remission.
  • Mechanisms include immunomodulation and mucosal repair.

Conclusions:

  • Stem cell therapy is a promising emerging treatment for IBD, offering potential for inflammation alleviation and remission.
  • Further evaluation of safety and long-term efficacy is crucial for clinical implementation.
  • Stem cell transplantation presents a potential future treatment avenue for IBD.